Mymetics Corporation Share Price

MYMX

US62856A3005

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 17:02:13 11/05/2026 BST			5-day change	1st Jan Change
0.000300 ^USD	-.--%		-.--%	-

20/11/23	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/08/23	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI

on all subscriptions*

Exceptional extension!

Enjoy this offer

* See conditions under "Our services"

Valuation: Mymetics Corporation

Market Cap	439K 385K 355K 332K 623K 41.56M 633K 4.26M 1.65M 20.39M 1.65M 1.61M 70.88M	P/E 2021	-1.86x	P/E 2022	-1.77x
Enterprise Value	72.12M 63.36M 58.38M 54.65M 102M 6.83B 104M 701M 271M 3.35B 271M 265M 11.65B	EV / Sales 2021	177x	EV / Sales 2022	78x
Free-Float	99.88%	Yield 2021 *	-	Yield 2022	-

* Estimated data More valuation ratios

Latest news : Mymetics Corporation

20/11/23	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI
18/08/23	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	CI
15/05/23	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	CI
11/04/23	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2022	CI
10/04/23	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
17/01/23	Mymetics Corporation Appoints Marcel B. Rüegg to the Board	CI
28/12/22	Mymetics Corporation Announces Resignation of Ernest M. Stern as A Member of the Board of Directors	CI
14/11/22	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	CI
11/08/22	Mymetics Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	CI
13/05/22	Mymetics Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	CI
31/03/22	Mymetics Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	CI
30/03/22	Mymetics Corporation Auditor Raises 'Going Concern' Doubt	CI
12/11/21	Mymetics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI

More news

Press Releases: Mymetics Corporation

11/04/23	MYMETICS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
27/02/23	MYMETICS CORP : Other Events (form 8-K)	AQ
08/02/23	MYMETICS CORP : Other Events (form 8-K)	AQ
17/01/23	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ
28/12/22	MYMETICS CORP : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	AQ

More press releases

Managers and Directors: Mymetics Corporation

Manager	Title	Age	Since
Ronald Hugo Gerard Kempers CEO	Chief Executive Officer	58	18/11/2012

More insiders

Mymetics Corporation is a vaccine company. The Company is focused on developing vaccines for infectious diseases. The Company has over five vaccine candidates in its pipeline: human immunodeficiency virus type 1 (HIV-1)/acquired immune deficiency syndrome (AIDS), intra nasal Influenza, Malaria, Herpes Simplex Virus (HSV) and the Respiratory Syncitial Virus (RSV) vaccine. Its technology utilizes virosomes, lipid-based carriers containing functional fusion viral proteins and natural membrane proteins, in combination with rationally designed antigens. Its prophylactic HIV-1 vaccine candidate is constituted of virosomes linked to conserved antigens derived from the HIV-1 glycoprotein 41 (gp41) proteins from the clade B. The RSV vaccine consists of the reconstituted membrane of RSV containing the native viral proteins. The HSV vaccine candidate consists of the reconstituted membrane of HSV-1 or HSV-2. The intranasal influenza vaccine includes the reconstituted membrane of influenza virus.

Employees

Sector

Biotechnology & Medical Research

More about the company

Stock Market
Stocks
MYMX Stock

-40%: Exceptional extension

SEIZE THE OFFER!

Current year	0		0
1 year	0		0
3 years	0		48.8
5 years	0		230
10 years	0		380

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MYMETICS CORPORATION	-.--%	-.--%	-.--%	-100.00%	45
ARGENX SE	+2.14%	+7.57%	+74.46%	+123.84%	56.65B
WUXI APPTEC CO., LTD.	-0.49%	+8.30%	+62.88%	+67.95%	47.49B
BIONTECH SE	+0.48%	+1.25%	-12.03%	-15.42%	22.81B
INSMED INCORPORATED	+3.60%	+6.94%	-3.10%	+411.77%	21.37B
WUXI BIOLOGICS (CAYMAN) INC.	+1.30%	+3.73%	+27.10%	-17.51%	16.12B
GENMAB A/S	+3.20%	+9.80%	+26.27%	-34.74%	15.56B
EXELIXIS, INC.	-0.02%	-1.46%	+18.38%	+158.51%	12.91B
PHARMAESSENTIA CORPORATION	0.00%	+10.49%	+130.14%	+273.89%	12.86B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.43%	-6.44%	+21.49%	-	11.67B
Average	+1.16%	+2.81%	+34.56%	+96.48%	21.74B
Weighted average by Cap.	+1.26%	+4.82%	+45.40%	+113.90%

	2021	2022
Net sales	430K 378K 348K 326K 611K 40.73M 621K 4.18M 1.62M 19.99M 1.61M 1.58M 69.46M	1.03M 903K 832K 779K 1.46M 97.38M 1.48M 9.99M 3.87M 47.78M 3.86M 3.78M 166M
Net income	-4.73M -4.16M -3.83M -3.58M -6.72M -448M -6.83M -45.97M -17.8M -220M -17.76M -17.37M -764M	-4.8M -4.22M -3.89M -3.64M -6.82M -455M -6.94M -46.7M -18.08M -223M -18.04M -17.65M -776M
Net Debt	67.1M 58.95M 54.32M 50.85M 95.27M 6.36B 96.87M 652M 252M 3.12B 252M 246M 10.84B	71.68M 62.97M 58.03M 54.32M 102M 6.79B 103M 697M 270M 3.33B 269M 263M 11.58B

Mymetics Corporation Share Price

Stocks

MYMX

US62856A3005

Biotechnology & Medical Research

Valuation: Mymetics Corporation

Chart: Mymetics Corporation

Latest news : Mymetics Corporation

Press Releases: Mymetics Corporation

Course Extremes

Managers and Directors: Mymetics Corporation

Bio Therapeutic Drugs

Financials

Company Profile